Early data from a tiny trial suggest that a single CRISPR infusion can cut “bad” cholesterol and triglycerides in half. The hard questions now are less about biology and more about economics, safety and who should be offered an irreversible edit in the first place.
Heart disease meets “one-and-done” medicine
Cardiovascular disease remains the world’s leading killer. The World Health Organization estimates that about 19.8 million people died from cardiovascular causes in 2022—roughly 32% of all deaths globally, with most of them due to heart attacks and strokes.
Cholesterol and other blood fats sit at the centre of this story.
